Developmental Research Program

项目摘要/摘要（DRP） 乳腺癌通常具有特定的同源重组（HR）DNA修复缺陷（HRD）模式 和/或遗传不稳定性的特定模式，即染色体不稳定性（CIN）和APOBEC诱变。 这些改变存在于相当大比例的乳腺癌中，并且它们在转移性乳腺癌中富集。 疾病可靠地识别这些患者并确定这些患者的最佳治疗的生物标志物是 非常需要。发展研究计划（DRP）将在培养翻译能力方面发挥重要作用。 研究工作集中在乳腺癌，特别是研究解决特定模式的DNA修复 缺陷和/或遗传不稳定性及其分子基础。我们将使用DRP资金，并辅以强大的 承诺提供机构资金，以支持新的和现有的调查员开展创新项目， 这对产生诊断和治疗这一大部分乳腺癌的新想法至关重要。我们 目标是建立机制，为重要的新方向迅速供资，以加快实现 我们SPORE的转化研究目标。我们确定了一个可靠的投资组合， 研究项目，这将是竞争的支持，一旦该计划成立。我们将请求飞行员 大型MSKCC内临床和基础研究者的具有转化潜力的项目提案 社区，包括洛克菲勒大学，纽约长老会医院和威尔康奈尔医学院 康奈尔大学。然后，我们将在经过严格的同行评审后，选择最有前途的新项目进行支持 由领导委员会、内部咨询委员会和患者倡导者组成。外部意见 将根据需要征求审查员的意见。试点项目将获得1年的资助，但研究人员可以申请 明年通过同样的竞争过程获得额外的资金。每年的咨询和领导 委员会成员将开会审查每个研究项目，核心，职业提升项目， 发展试点项目。委员会成员将被要求评估是否有任何发展项目 已经取得了足够的进展，并显示出足够的平移潜力，以掩盖其中一个完整的孢子 研究项目。然后，委员会成员将投票并决定是否应进行任何开发项目 进入全面项目状态。如果是这样，预算将作适当调整，并提交大会批准。 NCI的TRP。

Project Abstract/ Summary (DRP) Breast cancers frequently harbor specific patterns of homologous recombination (HR) DNA repair defects (HRD) and/or specific patterns of genetic instability, namely chromosomal instability (CIN) and APOBEC mutagenesis. These alterations are present in a substantial proportion of breast cancers and they are enriched in metastatic disease. Biomarkers to identify these patients reliably and to define the optimal treatments for these patients are sorely needed. The Developmental Research Program (DRP) will play an important role in fostering translational research endeavors focusing on breast cancer, in particular research addressing specific patterns of DNA repair defects and/or genetic instability and their molecular basis. We will use DRP funding supplemented by a strong commitment of institutional funds to support innovative projects by new and established investigators, which are critical to the generation of new ideas in the diagnosis and treatment of this large subset of breast cancers. Our goal is to establish mechanisms for rapid funding of important new directions to accelerate progress towards the translational research goals of our SPORE. We identified a credible portfolio of promising developmental research projects, which will be competing for support once the program is established. We will request pilot project proposals with translational potential from clinical and basic investigators within the larger MSKCC community, including Rockefeller University, New York-Presbyterian Hospital and Weill Cornell Medical College of Cornell University. We will then select the most promising new projects for support after rigorous peer review by the Leadership Committee, the Internal Advisory Board and the Patient Advocates. The opinion of external reviewers will be solicited as needed. Pilot projects will be funded for 1 year, but investigators may apply for additional funding through this same competitive process the next year. Every year the Advisory and Leadership Committee members will meet to review each research project, core, career enhancement project and developmental pilot project. Committee members will be asked to assess whether any developmental project has progressed sufficiently and shown enough translational potential, so as to eclipse one of the full SPORE Research Projects. The committee members will then vote and decide whether any developmental project should be advanced to full project status. If so, the budgets will be appropriately adjusted and sent for approval with the TRP of the NCI.